Blastomycosis medical therapy

Blastomycosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Blastomycosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Blastomycosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Blastomycosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Blastomycosis medical therapy
CDC on Blastomycosis medical therapy
Blastomycosis medical therapy in the news
Blogs on Blastomycosis medical therapy
Directions to Hospitals Treating Blastomycosis
Risk calculators and risk factors for Blastomycosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]Aditya Ganti M.B.B.S. [3]

Overview

As per the guidelines given by the Infectious Diseases Society of America the appropriate regimen must be guided by the clinical form and severity of disease, as well as the immune status of patient and toxicity of antifungal agents. Only asymptomatic infections are left untreated, otherwise all cases need therapy.

• Immunocompetent patient. (Non-Life threatening infection): Drug of choice in this cases is usually Itraconazole or Lipid Amphotericin B. Alternatively, daily fluconazole or w may also be used.

• Immunocompetent patient. (Life threatening infection)
  • Pulmonary cases - These warrant treatment primarily with Lipid Amphotericin B or Deoxycholate Amphotericin B. Once the condition has been stabilized the patient may be switched to oral Itraconazole therapy.
  • Disseminated cases - Drug of choice is same, however patients non tolerant to Amphotericin B can be treated with fluconazole or Itraconazole.

• Immunocompromised patients: All patients warrant treatment with Lipid Amphotericin B as the drug of choice and Itraconazole once the disease has shown clinical improvement.

Medical Therapy

Antimicrobial Regimen

• Blastomycosis

• Mild to moderate pulmonary blastomycosis

• Preferred regimen: Itraconazole 200 mg PO q12-24h for 6–12 months
• Note:Initially oral Itraconazole, 200 mg for 3 days and then q12-24h for 6–12 months, is recommended

• Moderately severe to severe pulmonary blastomycosis

• Preferred regimen(1): Lipid amphotericin B (Lipid AmB) 3–5 mg/kg IV q 24h for 1–2 weeks AND Itraconazole 200 mg PO q 12h for 6–12 months
• Preferred regimen(2): Amphotericin B deoxycholate 0.7–1 mg/kg IV q 24h for 1–2 weeks AND Itraconazole 200 mg PO q 12h for 6–12 months
• Note: Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h for 6–12 months, is recommended

• Mild to moderate disseminated blastomycosis

• Preferred regimen: Itraconazole 200 mg PO q12-24h for 6–12 months
• Note(1): Treat osteoarticular disease for 12 months
• Note(2): Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h for a total of 6–12 months, is recommended

• Moderately severe to severe disseminated blastomycosis

• Preferred regimen(1): Lipid amphotericin B(Lipid AmB) 3–5 mg/kg IV q24h for 1–2 weeks AND Itraconazole 200 mg PO q12h for 6–12 months
• Preferred regimen(2): Amphotericin B deoxycholate 0.7–1 mg/kg IV q24h for 1–2 weeks AND Itraconazole 200 mg PO q12h for 6–12 months
• Note: oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h, for a total of 6–12 months, is recommended

• CNS disease

• Preferred regimen: Lipid amphotericin B (Lipid AmB) IV 5 mg/kg q24h for 4–6 weeks AND an oral azole for at least 1 year
• Note(1): Step-down therapy can be with Fluconazole, 800 mg per day OR Itraconazole, 200 mg q8-12h per day OR voriconazole, 200–400 mg q12h
• Note(2): Longer treatment may be required for immunosuppressed patients.

• Immunosuppressed patients

• Preferred regimen(1): Lipid amphotericin B (Lipid AmB), 3–5 mg/kg IV q24h for 1–2 weeks, AND Itraconazole, 200 mg PO q12h for 12 months
• Preferred regimen(2): Amphotericin B deoxycholate, 0.7–1 mg/kg IV q24h, for 1–2 weeks, AND Itraconazole, 200 mg POq12h for 12 months
• Note(1): Oral Itraconazole, 200 mg q8h for 3 days and then 200 mg q12h, for a total of 12 months, is recommended
• Note(2): Life-long suppressive treatment may be required if immunosuppression cannot be reversed.

• Pregnant women

• Preferred regimen: Lipid amphotericin B (Lipid AmB) 3–5 mg/kg IV q24h
• Note(1): Azoles should be avoided because of possible teratogenicity
• Note(2): If the newborn shows evidence of infection, treatment is recommended with Amphotericin B deoxycholate, 1.0 mg/kg IV q24h

• Children with mild to moderate disease

• Preferred regimen: Itraconazole 10 mg/kg PO q24h for 6–12 months
• Note: Maximum dose 400 mg q24h

• Children with moderately severe to severe disease

• Preferred regimen(1): Amphotericin B deoxycholate 0.7–1 mg/kg IV q24h for 1–2 weeks AND Itraconazole 10 mg/kg PO q24h to a maximum of 400 mg q24h for 6–12 months
• Preferred regimen(2): Lipid amphotericin B (Lipid AmB) 3–5 mg/kg IV q24h for 1–2 weeks AND Itraconazole 10 mg/kg PO q24h to a maximum of 400 mg q24h for 6–12 months
• Note: Children tolerate Amphotericin B deoxycholate better than adults do.